Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SparingVision logo — Genomic Medicines For Ocular Diseases

SparingVision

Genomic Medicines For Ocular Diseases

Founded 2016 France France 49 employees Series B Total: $119.50M Biotechnology, Health Care +1

General Information

Company Name SparingVision
Founded Year 2016
Location France France +1
Founders / Decision Makers
Team member
Employees 49
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series B
Social

Get notified when SparingVision moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SparingVision

SparingVision is a biotechnology startup dedicated to developing genomic medicines for ocular diseases. Founded in 2016, the company aims to revolutionize the treatment of ocular diseases by translating over 20 years of world-leading ophthalmic research into vision-saving therapies. The core focus of SparingVision's work is on addressing rod-cone dystrophies, specifically targeting retinitis pigmentosa (RP), the most common inherited retinal disease globally, affecting two million people. The company's lead products, SPVN06 and SPVN20, are designed to address mid and late stages of RP, offering potential applications for various retinal diseases, irrespective of genetic cause. Notably, SparingVision has attracted significant investments amounting to a total of €60 million from a strong syndicate of backers including 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital, and Ysios Capital. Most recently, the company secured a €75.00M Series B investment on 14 September 2022 with participation from 4BIO Capital, Bpifrance, Jeito Capital, Ysios Capital, Retinal Degeneration Fund, and UPMC Enterprises. Based in France, SparingVision is supported by a strong, internationally renowned team committed to leveraging the potential of genomic medicine to rapidly deliver new treatments to ocular disease patients. With a focus on gene independent treatments, SparingVision is poised to bring about a paradigm shift in ocular disease therapeutics. For more information, visit www.sparingvision.com.

Taxonomy: Genomic Medicines, Ocular Diseases, Inherited Retinal Diseases, Gene-independent Treatments, Research and Development, Retinitis Pigmentosa, Vision-Saving Treatments, Investment, Therapeutic Innovation, Pipeline Development, Rare Disease Treatment, International Collaboration, Sight-saving Treatments, Venture Capital

Services & Products

Development and delivery of innovative genomic medicines for ocular diseases

Target Customers

Patients affected by inherited retinal diseases and ocular disorders

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		14 Sep 2022
Corporate Round •••••• 1
Investor
13 Oct 2021
Series A •••••• 3
Investor Investor Investor
21 Oct 2020

SparingVision Alternatives & Competitors

SparingVision vs
Tern Therapeutics
Tern Therapeutics United States

Going to the ends of the Earth to develop new gene therapies for rare diseases

6 employees
SparingVision vs
REGENXBIO
REGENXBIO United States

Seeking to improve lives through the curative potential of gene therapy.

IPO
389 employees
Biopharma, Biotechnology
Compare SparingVision vs REGENXBIO
SparingVision vs
Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. United States

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experienc...

Post Ipo Equity
325 employees
Biotechnology, Health Care
Compare SparingVision vs Ocular Therapeutix, Inc.
Also compare with: SparingVision vs Locanabio, Inc. Locanabio, Inc.

FAQ About SparingVision

Genomic Medicines For Ocular Diseases
SparingVision was founded in 2016.
SparingVision is headquartered in France.
SparingVision operates in the following industries: Biotechnology, Health Care, Life Sciences.
SparingVision has approximately 49 employees.
SparingVision has completed 3 funding rounds, raising a total of $119.50M. The latest funding stage is Series B.
SparingVision offers: Development and delivery of innovative genomic medicines for ocular diseases.
Top alternatives and competitors to SparingVision include Tern Therapeutics, REGENXBIO, Ocular Therapeutix, Inc., Locanabio, Inc., GenSight Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SparingVision and Tern Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors SparingVision and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy